[{"id":"1c2892ea-1261-4dae-afe1-c46131b3f056","acronym":"","url":"https://clinicaltrials.gov/study/NCT07039760","created_at":"2025-06-28T13:40:51.525Z","updated_at":"2025-06-28T13:40:51.525Z","phase":"Phase 1","brief_title":"Asciminib With or Without Sildenafil for Brain Tumors","source_id_and_acronym":"NCT07039760","lead_sponsor":"Washington University School of Medicine","biomarkers":" CRKL • ABL2","pipe":"","alterations":" ","tags":["CRKL • ABL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Scemblix (asciminib) • sildenafil"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 12","initiation":"Initiation: 12/01/2025","start_date":" 12/01/2025","primary_txt":" Primary completion: 06/01/2027","primary_completion_date":" 06/01/2027","study_txt":" Completion: 06/01/2027","study_completion_date":" 06/01/2027","last_update_posted":"2025-06-26"},{"id":"47b96ada-e4a0-4b3c-9de2-04691e9ba258","acronym":"LAMP-2","url":"https://clinicaltrials.gov/study/NCT06889168","created_at":"2025-06-07T14:47:25.914Z","updated_at":"2025-06-07T14:47:25.914Z","phase":"Phase 1","brief_title":"Evaluating the Long-term Safety and Tolerability of Imatinib in Patients With Lymphangioleiomyomatosis (LAM)","source_id_and_acronym":"NCT06889168 - LAMP-2","lead_sponsor":"Columbia University","biomarkers":" VEGFD","pipe":"","alterations":" ","tags":["VEGFD"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e imatinib"],"overall_status":"Recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 06/01/2025","start_date":" 06/01/2025","primary_txt":" Primary completion: 06/01/2026","primary_completion_date":" 06/01/2026","study_txt":" Completion: 10/01/2026","study_completion_date":" 10/01/2026","last_update_posted":"2025-05-31"},{"id":"0a6aefb7-2166-498d-888e-ed54ef581ee3","acronym":"","url":"https://clinicaltrials.gov/study/NCT00792948","created_at":"2021-01-18T03:00:33.783Z","updated_at":"2025-02-25T12:25:29.112Z","phase":"Phase 2","brief_title":"Combination Chemotherapy With or Without Donor Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia","source_id_and_acronym":"NCT00792948","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" ABL1 • BCR • CD22 • CD5 • CD79A • MME • CD7 • ANPEP • MPO","pipe":"","alterations":" ","tags":["ABL1 • BCR • CD22 • CD5 • CD79A • MME • CD7 • ANPEP • MPO"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e dasatinib • cytarabine • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • methotrexate • vincristine • sirolimus • leucovorin calcium • Hemady (dexamethasone tablets) • Neupogen (filgrastim) • Starasid (cytarabine ocfosfate) • cyclophosphamide intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 97","initiation":"Initiation: 09/01/2009","start_date":" 09/01/2009","primary_txt":" Primary completion: 06/01/2016","primary_completion_date":" 06/01/2016","study_txt":" Completion: 01/06/2026","study_completion_date":" 01/06/2026","last_update_posted":"2025-02-24"},{"id":"a01c1d5f-e2a9-42b3-82b6-70a6e6b04112","acronym":"AALL1131","url":"https://clinicaltrials.gov/study/NCT02883049","created_at":"2021-01-18T14:09:12.849Z","updated_at":"2025-02-25T13:39:22.892Z","phase":"Phase 3","brief_title":"Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive Mutations","source_id_and_acronym":"NCT02883049 - AALL1131","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" ABL1 • BCR • RUNX1 • KMT2A • ETV6","pipe":" | ","alterations":" MLL rearrangement","tags":["ABL1 • BCR • RUNX1 • KMT2A • ETV6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MLL rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e dasatinib • cytarabine • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • methotrexate • vincristine • prednisone • daunorubicin • clofarabine • leucovorin calcium • Oncaspar liquid (pegaspargase) • mercaptopurine delayed release (DR6MP) • mercaptopurine • thioguanine • Hemady (dexamethasone tablets) • Starasid (cytarabine ocfosfate) • cyclophosphamide intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 5949","initiation":"Initiation: 02/29/2012","start_date":" 02/29/2012","primary_txt":" Primary completion: 12/31/2022","primary_completion_date":" 12/31/2022","study_txt":" Completion: 10/03/2025","study_completion_date":" 10/03/2025","last_update_posted":"2025-02-21"},{"id":"a8dbbb89-8bb1-4f12-ad96-eb67e83dce09","acronym":"","url":"https://clinicaltrials.gov/study/NCT00265798","created_at":"2021-01-18T00:54:12.869Z","updated_at":"2025-02-25T13:47:55.628Z","phase":"Phase 2","brief_title":"Sorafenib in Treating Patients With Malignant Gastrointestinal Stromal Tumor That Progressed During or After Previous Treatment With Imatinib Mesylate and Sunitinib Malate","source_id_and_acronym":"NCT00265798","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" KIT","pipe":" | ","alterations":" KIT expression","tags":["KIT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KIT expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e sorafenib • imatinib • sunitinib"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 38","initiation":"Initiation: 09/14/2005","start_date":" 09/14/2005","primary_txt":" Primary completion: 02/11/2010","primary_completion_date":" 02/11/2010","study_txt":" Completion: 03/08/2025","study_completion_date":" 03/08/2025","last_update_posted":"2025-02-20"},{"id":"39a3ce34-fc3f-4772-a312-5b10b9a2eacf","acronym":"","url":"https://clinicaltrials.gov/study/NCT00390793","created_at":"2022-04-24T08:54:27.800Z","updated_at":"2025-02-25T14:06:37.175Z","phase":"Phase 2","brief_title":"Combination Chemotherapy and Dasatinib in Treating Participants With Philadelphia Positive or BCR-ABL Positive Acute Lymphoblastic Leukemia.","source_id_and_acronym":"NCT00390793","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" ABL1 • BCR","pipe":"","alterations":" ","tags":["ABL1 • BCR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e dasatinib • cytarabine • doxorubicin hydrochloride • cyclophosphamide • methotrexate • vincristine • prednisone • daunorubicin • Starasid (cytarabine ocfosfate)"],"overall_status":"Completed","enrollment":" Enrollment 107","initiation":"Initiation: 09/28/2006","start_date":" 09/28/2006","primary_txt":" Primary completion: 02/02/2024","primary_completion_date":" 02/02/2024","study_txt":" Completion: 02/02/2024","study_completion_date":" 02/02/2024","last_update_posted":"2025-02-17"},{"id":"463898f9-d0f2-4eeb-ad5a-ad7d4f465a1f","acronym":"ASC4MORE","url":"https://clinicaltrials.gov/study/NCT03578367","created_at":"2021-01-18T17:36:31.183Z","updated_at":"2025-02-25T14:39:57.704Z","phase":"Phase 2","brief_title":"Study of Efficacy and Safety of Asciminib in Combination With Imatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP)","source_id_and_acronym":"NCT03578367 - ASC4MORE","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" ABL1 • BCR","pipe":"","alterations":" ","tags":["ABL1 • BCR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e imatinib • nilotinib • Scemblix (asciminib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 84","initiation":"Initiation: 11/22/2018","start_date":" 11/22/2018","primary_txt":" Primary completion: 11/08/2021","primary_completion_date":" 11/08/2021","study_txt":" Completion: 02/27/2025","study_completion_date":" 02/27/2025","last_update_posted":"2025-02-14"},{"id":"4031ba62-5860-47d7-91f9-d7064a25a760","acronym":"","url":"https://clinicaltrials.gov/study/NCT04795427","created_at":"2021-03-12T15:52:52.806Z","updated_at":"2025-02-25T15:12:00.303Z","phase":"Phase 2","brief_title":"Study of Efficacy and Safety of CML-CP Patients Treated With Asciminib Versus Best Available Therapy, Previously Treated With 2 or More Tyrosine Kinase Inhibitors","source_id_and_acronym":"NCT04795427","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" ABL1 • BCR","pipe":"","alterations":" ","tags":["ABL1 • BCR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Scemblix (asciminib)"],"overall_status":"Completed","enrollment":" Enrollment 84","initiation":"Initiation: 12/06/2021","start_date":" 12/06/2021","primary_txt":" Primary completion: 05/29/2023","primary_completion_date":" 05/29/2023","study_txt":" Completion: 11/18/2024","study_completion_date":" 11/18/2024","last_update_posted":"2025-02-13"},{"id":"63139aa8-19bf-4602-a810-5c7110a10962","acronym":"","url":"https://clinicaltrials.gov/study/NCT04423185","created_at":"2021-01-18T21:18:39.174Z","updated_at":"2025-02-25T15:26:22.079Z","phase":"Phase 2","brief_title":"PLATFORM Study of Precision Medicine for Rare Tumors","source_id_and_acronym":"NCT04423185","lead_sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","biomarkers":" EGFR • HER-2 • BRAF • ALK • MET • BRCA1 • BRCA2 • KIT • ROS1 • CDKN2A","pipe":" | ","alterations":" BRCA2 mutation • BRCA1 mutation • EGFR mutation • HER-2 overexpression • BRAF mutation • HER-2 amplification • MET amplification • KIT mutation • ALK fusion • ROS1 fusion • CDKN2A mutation • MET mutation • BRAF amplification","tags":["EGFR • HER-2 • BRAF • ALK • MET • BRCA1 • BRCA2 • KIT • ROS1 • CDKN2A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA2 mutation • BRCA1 mutation • EGFR mutation • HER-2 overexpression • BRAF mutation • HER-2 amplification • MET amplification • KIT mutation • ALK fusion • ROS1 fusion • CDKN2A mutation • MET mutation • BRAF amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Xalkori (crizotinib) • Tecentriq (atezolizumab) • Ibrance (palbociclib) • Zelboraf (vemurafenib) • imatinib • Tyvyt (sintilimab) • Alecensa (alectinib) • Zejula (niraparib) • Irene (pyrotinib) • Ameile (aumolertinib) • Vizimpro (dacomitinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 770","initiation":"Initiation: 08/15/2020","start_date":" 08/15/2020","primary_txt":" Primary completion: 07/01/2026","primary_completion_date":" 07/01/2026","study_txt":" Completion: 07/01/2028","study_completion_date":" 07/01/2028","last_update_posted":"2025-02-11"},{"id":"03bbf3c8-c3f3-4829-8090-3434c8fc4bb8","acronym":"ASC4START","url":"https://clinicaltrials.gov/study/NCT05456191","created_at":"2022-07-13T12:56:30.124Z","updated_at":"2025-02-25T16:46:11.226Z","phase":"Phase 3","brief_title":"A Study to Investigate Tolerability and Efficacy of Asciminib (Oral) Versus Nilotinib (Oral) in Adult Participants (≥18 Years of Age) With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Chronic Phase (Ph+ CML-CP)","source_id_and_acronym":"NCT05456191 - ASC4START","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" ABL1","pipe":"","alterations":" ","tags":["ABL1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e nilotinib • Scemblix (asciminib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 574","initiation":"Initiation: 11/21/2022","start_date":" 11/21/2022","primary_txt":" Primary completion: 03/17/2025","primary_completion_date":" 03/17/2025","study_txt":" Completion: 07/07/2031","study_completion_date":" 07/07/2031","last_update_posted":"2025-02-06"},{"id":"d6077c21-17bb-4f1e-9fd6-5e8d472b76ab","acronym":"","url":"https://clinicaltrials.gov/study/NCT03854903","created_at":"2021-01-18T19:01:32.210Z","updated_at":"2025-02-25T16:37:21.932Z","phase":"Phase 1","brief_title":"WI231696: Bosutinib, Palbocicilib and Fulvestrant for HR+HER2- Advanced Breast Cancer Refractory to a CDK4/6 Inhibitor","source_id_and_acronym":"NCT03854903","lead_sponsor":"Georgetown University","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" ER positive • HER-2 negative • PGR positive • HER-2 negative + AR positive + ER positive • HER-2 negative + ER positive","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HER-2 negative • PGR positive • HER-2 negative + AR positive + ER positive • HER-2 negative + ER positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ibrance (palbociclib) • fulvestrant • bosutinib"],"overall_status":"Completed","enrollment":" Enrollment 19","initiation":"Initiation: 04/01/2019","start_date":" 04/01/2019","primary_txt":" Primary completion: 11/01/2023","primary_completion_date":" 11/01/2023","study_txt":" Completion: 01/09/2025","study_completion_date":" 01/09/2025","last_update_posted":"2025-02-06"},{"id":"fdf62ac7-f79d-46b1-9a07-c4ce7608d067","acronym":"Ascembl","url":"https://clinicaltrials.gov/study/NCT03106779","created_at":"2021-01-17T17:34:34.885Z","updated_at":"2025-02-25T16:36:53.037Z","phase":"Phase 3","brief_title":"Study of Efficacy of CML-CP Patients Treated With ABL001 Versus Bosutinib, Previously Treated With 2 or More TKIs","source_id_and_acronym":"NCT03106779 - Ascembl","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" ABL1 • BCR","pipe":" | ","alterations":" BCR-ABL1 mutation","tags":["ABL1 • BCR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BCR-ABL1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e bosutinib • Scemblix (asciminib)"],"overall_status":"Completed","enrollment":" Enrollment 233","initiation":"Initiation: 10/26/2017","start_date":" 10/26/2017","primary_txt":" Primary completion: 05/25/2020","primary_completion_date":" 05/25/2020","study_txt":" Completion: 12/04/2024","study_completion_date":" 12/04/2024","last_update_posted":"2025-02-06"},{"id":"1fb9a843-c4ef-444b-994a-39091f7c4fca","acronym":"ENESTop","url":"https://clinicaltrials.gov/study/NCT01698905","created_at":"2021-01-19T06:04:36.924Z","updated_at":"2025-02-25T17:35:30.294Z","phase":"Phase 2","brief_title":"Treatment-free Remission After Achieving Sustained MR4.5 on Nilotinib (ENESTop)","source_id_and_acronym":"NCT01698905 - ENESTop","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" ABL1 • BCR","pipe":"","alterations":" ","tags":["ABL1 • BCR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e nilotinib"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 163","initiation":"Initiation: 12/20/2012","start_date":" 12/20/2012","primary_txt":" Primary completion: 11/26/2015","primary_completion_date":" 11/26/2015","study_txt":" Completion: 01/19/2025","study_completion_date":" 01/19/2025","last_update_posted":"2025-01-29"},{"id":"8ee6a642-903b-4775-8ffb-3149fa1ecff5","acronym":"ENESTFreedom","url":"https://clinicaltrials.gov/study/NCT01784068","created_at":"2021-01-17T17:35:07.021Z","updated_at":"2025-02-25T17:35:31.954Z","phase":"Phase 2","brief_title":"Nilotinib Treatment-free Remission Study in CML (Chronic Myeloid Leukemia) Patients","source_id_and_acronym":"NCT01784068 - ENESTFreedom","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" ABL1 • BCR","pipe":" | ","alterations":" BCR-ABL1 E255K • BCR-ABL1 Y253H","tags":["ABL1 • BCR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BCR-ABL1 E255K • BCR-ABL1 Y253H"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e nilotinib"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 215","initiation":"Initiation: 03/04/2013","start_date":" 03/04/2013","primary_txt":" Primary completion: 05/31/2016","primary_completion_date":" 05/31/2016","study_txt":" Completion: 01/24/2025","study_completion_date":" 01/24/2025","last_update_posted":"2025-01-29"},{"id":"91bc7864-fd10-46ec-b629-e98e5ba03f9b","acronym":"","url":"https://clinicaltrials.gov/study/NCT06773936","created_at":"2025-02-25T15:46:10.278Z","updated_at":"2025-02-25T15:46:10.278Z","phase":"Phase 2","brief_title":"Adding Asciminib to Usual Treatment for Adults with Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia","source_id_and_acronym":"NCT06773936","lead_sponsor":"SWOG Cancer Research Network","biomarkers":" ABL1 • BCR","pipe":"","alterations":" ","tags":["ABL1 • BCR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e dasatinib • Blincyto (blinatumomab) • prednisone • Scemblix (asciminib)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 55","initiation":"Initiation: 03/31/2025","start_date":" 03/31/2025","primary_txt":" Primary completion: 03/01/2029","primary_completion_date":" 03/01/2029","study_txt":" Completion: 05/01/2033","study_completion_date":" 05/01/2033","last_update_posted":"2025-01-14"},{"id":"e17fb339-f241-4fee-96fe-598ffffcf271","acronym":"ASC4REAL","url":"https://clinicaltrials.gov/study/NCT06684964","created_at":"2025-02-26T07:06:31.325Z","updated_at":"2025-02-26T07:06:31.325Z","phase":"","brief_title":"RWE,NIS,Prospective Study for the Effectiveness, Tolerability and Adherence of Asciminib in Saudi Arabia. (ASC4REAL)","source_id_and_acronym":"NCT06684964 - ASC4REAL","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" ABL1 • BCR","pipe":"","alterations":" ","tags":["ABL1 • BCR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Scemblix (asciminib)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 01/30/2025","start_date":" 01/30/2025","primary_txt":" Primary completion: 07/30/2026","primary_completion_date":" 07/30/2026","study_txt":" Completion: 07/30/2026","study_completion_date":" 07/30/2026","last_update_posted":"2025-01-10"},{"id":"472eb807-ca9c-41c2-9b36-97f85b9dac47","acronym":"","url":"https://clinicaltrials.gov/study/NCT06754267","created_at":"2025-02-26T07:54:58.245Z","updated_at":"2025-02-26T07:54:58.245Z","phase":"Phase 2","brief_title":"Venetoclax Combined With Olverembatinib and Predinisone in Treating Ph+ B-ALL","source_id_and_acronym":"NCT06754267","lead_sponsor":"First Affiliated Hospital of Zhejiang University","biomarkers":" ABL1","pipe":"","alterations":" ","tags":["ABL1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • Nailike (olverembatinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 36","initiation":"Initiation: 12/01/2024","start_date":" 12/01/2024","primary_txt":" Primary completion: 12/30/2025","primary_completion_date":" 12/30/2025","study_txt":" Completion: 12/30/2027","study_completion_date":" 12/30/2027","last_update_posted":"2024-12-31"},{"id":"0adc2fbc-6b3e-4f34-8de8-ac2947fe1dfb","acronym":"","url":"https://clinicaltrials.gov/study/NCT00070499","created_at":"2021-01-18T00:10:44.565Z","updated_at":"2025-02-25T16:21:43.510Z","phase":"Phase 2","brief_title":"Imatinib Mesylate or Dasatinib in Treating Patients With Previously Untreated Chronic Phase Chronic Myelogenous Leukemia","source_id_and_acronym":"NCT00070499","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" ABL1 • BCR","pipe":"","alterations":" ","tags":["ABL1 • BCR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e dasatinib • imatinib"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 406","initiation":"Initiation: 08/15/2004","start_date":" 08/15/2004","primary_txt":" Primary completion: 11/01/2010","primary_completion_date":" 11/01/2010","study_txt":" Completion: 02/22/2025","study_completion_date":" 02/22/2025","last_update_posted":"2024-12-27"},{"id":"d9427140-13fb-4cb7-b7fe-49c1e6486504","acronym":"","url":"https://clinicaltrials.gov/study/NCT03595917","created_at":"2022-04-24T08:59:32.242Z","updated_at":"2025-02-25T15:43:07.761Z","phase":"Phase 1","brief_title":"ABL001 + Dasatinib + Prednisone + Blinatumomab in BCR-ABL+ B-ALL or CML","source_id_and_acronym":"NCT03595917","lead_sponsor":"Marlise Luskin, MD","biomarkers":" ABL1 • BCR","pipe":"","alterations":" ","tags":["ABL1 • BCR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e dasatinib • Blincyto (blinatumomab) • prednisone • Scemblix (asciminib)"],"overall_status":"Recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 07/24/2018","start_date":" 07/24/2018","primary_txt":" Primary completion: 11/01/2025","primary_completion_date":" 11/01/2025","study_txt":" Completion: 11/01/2026","study_completion_date":" 11/01/2026","last_update_posted":"2024-12-27"},{"id":"de0eb004-7071-4d0b-b9a0-5aa41fe0d166","acronym":"PInNACLe","url":"https://clinicaltrials.gov/study/NCT02001818","created_at":"2021-01-18T09:08:24.888Z","updated_at":"2025-02-25T15:41:09.436Z","phase":"Phase 2","brief_title":"Pegylated Interferon Alfa-2b and Nilotinib for Augmentation of Complete Molecular Response in Chronic Myeloid Leukaemia","source_id_and_acronym":"NCT02001818 - PInNACLe","lead_sponsor":"Australasian Leukaemia and Lymphoma Group","biomarkers":" ABL1 • BCR","pipe":"","alterations":" ","tags":["ABL1 • BCR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e imatinib • nilotinib • ViraferonPeg (peginterferon-α-2b)"],"overall_status":"Completed","enrollment":" Enrollment 60","initiation":"Initiation: 04/11/2014","start_date":" 04/11/2014","primary_txt":" Primary completion: 01/07/2022","primary_completion_date":" 01/07/2022","study_txt":" Completion: 01/07/2022","study_completion_date":" 01/07/2022","last_update_posted":"2024-08-06"},{"id":"67208ab2-da0d-429c-a27e-8240b35e734d","acronym":"ASC4TARGET","url":"https://clinicaltrials.gov/study/NCT06514534","created_at":"2025-02-26T09:29:56.710Z","updated_at":"2025-02-26T09:29:56.710Z","phase":"Phase 2","brief_title":"Open-label Study of Asciminib for CML-CP or CML-AP Patients With T315I Mutation Who Are Resistant, Intolerant or Ineligible to Ponatinib.","source_id_and_acronym":"NCT06514534 - ASC4TARGET","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" ABL1 • BCR","pipe":"","alterations":" ","tags":["ABL1 • BCR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Iclusig (ponatinib) • Scemblix (asciminib)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 12/02/2024","start_date":" 12/02/2024","primary_txt":" Primary completion: 12/01/2028","primary_completion_date":" 12/01/2028","study_txt":" Completion: 12/01/2028","study_completion_date":" 12/01/2028","last_update_posted":"2024-07-23"},{"id":"aadf45af-534e-4166-a814-b17b7ba47bd0","acronym":"","url":"https://clinicaltrials.gov/study/NCT06516029","created_at":"2025-02-26T09:29:57.175Z","updated_at":"2025-02-26T09:29:57.175Z","phase":"","brief_title":"Real-World Evaluation of Patient Characteristics and Treatment Patterns Among Patients With CML-CP Treated With Asciminib","source_id_and_acronym":"NCT06516029","lead_sponsor":"Novartis","biomarkers":" ABL1","pipe":"","alterations":" ","tags":["ABL1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Scemblix (asciminib)"],"overall_status":"Completed","enrollment":" Enrollment 111","initiation":"Initiation: 04/21/2023","start_date":" 04/21/2023","primary_txt":" Primary completion: 10/02/2023","primary_completion_date":" 10/02/2023","study_txt":" Completion: 10/02/2023","study_completion_date":" 10/02/2023","last_update_posted":"2024-07-23"},{"id":"0d376833-0db0-4c3f-a481-a0fdb012621c","acronym":"","url":"https://clinicaltrials.gov/study/NCT04449549","created_at":"2021-01-18T21:24:29.334Z","updated_at":"2024-07-02T16:34:25.844Z","phase":"Phase 2","brief_title":"Rapid Analysis and Response Evaluation of Combination Anti-Neoplastic Agents in Rare Tumors (RARE CANCER) Trial: RARE 1 Nilotinib and Paclitaxel","source_id_and_acronym":"NCT04449549","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" NF1","pipe":"","alterations":" ","tags":["NF1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e paclitaxel • nilotinib"],"overall_status":"Recruiting","enrollment":" Enrollment 34","initiation":"Initiation: 08/24/2020","start_date":" 08/24/2020","primary_txt":" Primary completion: 04/02/2025","primary_completion_date":" 04/02/2025","study_txt":" Completion: 04/08/2025","study_completion_date":" 04/08/2025","last_update_posted":"2024-06-14"},{"id":"4d2a06b2-d858-435f-8f2c-4ebc80c32731","acronym":"","url":"https://clinicaltrials.gov/study/NCT00254423","created_at":"2021-01-18T00:51:48.619Z","updated_at":"2024-07-02T16:34:26.966Z","phase":"Phase 2","brief_title":"Dasatinib in Treating Patients With Early Chronic Phase Chronic Myelogenous Leukemia","source_id_and_acronym":"NCT00254423","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" ABL1 • BCR • IFNA1","pipe":"","alterations":" ","tags":["ABL1 • BCR • IFNA1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e dasatinib"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 156","initiation":"Initiation: 11/08/2005","start_date":" 11/08/2005","primary_txt":" Primary completion: 11/30/2024","primary_completion_date":" 11/30/2024","study_txt":" Completion: 11/30/2024","study_completion_date":" 11/30/2024","last_update_posted":"2024-06-12"}]